Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

IntroductionDespite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as a salvage therapy for patients with T790M mutation, resistance to osimertinib is common in the clinic...

Full description

Bibliographic Details
Main Authors: Ziying Lin, Qiwei Wang, Tao Jiang, Weihua Wang, Jean J. Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
lung cancer
EGFR-mutant
Osimertinib
STING agonist
tumor-associated macrophages
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1077203/full

Similar Items

Similar Items